Abstract 4385
Background
For cancer prevention and early diagnostics oncological awareness of the ordinary people is crucial. The knowledge of the problem is extremely important in young population. The aim of the study was to assess the basic oncological knowledge of high school students.
Methods
The study was conducted among high school students in Olsztyn in Poland between April 2017 and April 2018. It was a part of a health promotion program focused on oncological education for high school students in Warmia and Mazury District. The examination was carried out at the beginning of lectures conducted by medical students. The respondents filled in a questionnaire especially prepared for this study. Participation in the study was voluntary and anonymous. The chi-square test was used to compare the subgroups. A p-value <0.05 was considered significant. Statistical analysis was done using STATISTICA software 13.1 (Statsoft, Poland).
Results
The study was done on 227 students (age 17-18 years) from 5 high schools in Olsztyn. There were 125 female and 101 male (one unknown). Almost 80% of responders could correctly defined cancer disease. 153 students (67%) believed genetic predispositions to be the greatest factor affecting cancer morbidity. At the same time, 183 responders (81%) claimed that people have an impact on cancer development. But only 19% students indicated smoking as an important cancerogenous factor and none alcohol. Diet and physical activity influence on cancer prevalence were known only by 5 and 2 students, respectively. Over half of students (58%) thought they lead a healthy lifestyle, but almost 1/3 respondents smoke cigarettes. All students except eight (97%) believed that early detected cancer can be successfully treated. There was no difference depending on sex and place of residence in all questions.
Conclusions
The impact of genetic predispositions in neoplastic diseases seems to be overestimated by high school students. Students knew that lifestyle has an impact on cancer disease, but they did not associate smoking, alcohol, diet, physical activity with a healthy lifestyle. There is a need for more education about cancer and its’ prophylactic among high school students in Poland.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract